News
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...
Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback